An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients
NCT ID: NCT02231944
Last Updated: 2018-02-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
1997-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To evaluate Replenine®-VF in terms of long-term clinical efficacy, tolerance and safety
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years
NCT02263469
A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B
NCT02263456
A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.
NCT02250560
An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery
NCT02250573
Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen
NCT01757405
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Replenine®-VF
Replenine®-VF (High Purity Factor IX)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Replenine®-VF (High Purity Factor IX)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 12 years of age
* Severe Haemophilia B and without inhibitor to factor IX
Exclusion Criteria
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bio Products Laboratory
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Klinika Hematologii Instytutu Medycyny Wewnetrznej
Lodz, , Poland
Klinika Hematologii AM Lublin, ul.Jaczewskiego 8
Lublin, , Poland
Addenbrooke's Hospital, Hills Road
Cambridge, , United Kingdom
University Hospital of Wales, Heath Park
Cardiff, , United Kingdom
The Royal London Hospital
London, , United Kingdom
Manchester Royal Infirmary, Oxford Road
Manchester, , United Kingdom
Norwich and Norfolk Hospital
Norwich, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R9VFSE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.